Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

AMITRIPTYLINE HYDROCHLORIDE CRS (10 MG)

AMITRIPTYLINE HYDROCHLORIDE CRS (10 MG)

549-18-8

DISCOVER
BENDROFLUMETHIAZIDE IMPURITY A CRS (5 MG)

BENDROFLUMETHIAZIDE IMPURITY A CRS (5 MG)

211-506-8

DISCOVER
BETA-ACETYLDIGOXIN CRS (50 MG)

BETA-ACETYLDIGOXIN CRS (50 MG)

5355-48-6

DISCOVER
CEFRADINE FOR PEAK IDENTIFICATION CRS (15 MG)

CEFRADINE FOR PEAK IDENTIFICATION CRS (15 MG)

38821-53-3

DISCOVER
CHLOROGENIC ACID CRS (25 MG)

CHLOROGENIC ACID CRS (25 MG)

327-97-9

DISCOVER
Clobetasol for peak identification

Clobetasol for peak identification

25122-46-7

DISCOVER
CLOBETASOL IMPURITY J CRS (0.4 MG)

CLOBETASOL IMPURITY J CRS (0.4 MG)

NA

DISCOVER
ETIDRONATE DISODIUM CRS (10 MG)

ETIDRONATE DISODIUM CRS (10 MG)

7414-83-7

DISCOVER
FLUCONAZOLE IMPURITY B CRS (15 MG)

FLUCONAZOLE IMPURITY B CRS (15 MG)

NA

DISCOVER
FLUCONAZOLE IMPURITY C CRS (20 MG)

FLUCONAZOLE IMPURITY C CRS (20 MG)

NA

DISCOVER
LORAZEPAM FOR SYSTEM SUITABILITY CRS - * PSY (LORAZEPAM) (0.

LORAZEPAM FOR SYSTEM SUITABILITY CRS - * PSY (LORAZEPAM) (0.

846-49-1

DISCOVER
PANCURONIUM BROMIDE FOR SYSTEM SUITABILITY CRS (15 MG)

PANCURONIUM BROMIDE FOR SYSTEM SUITABILITY CRS (15 MG)

15500-66-0

DISCOVER